Skip to main content

Advertisement

SpringerLink
Log in

Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Tiacci E, Trifonov V, Schiavon G et al (2011) Braf mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Dietrich S, Glimm H, Andrulis M et al (2012) Braf inhibition in refractory hairy-cell leukemia. N Engl J Med 366:2038–2040

    Article  PubMed  Google Scholar 

  3. Peyrade F, Re D, Ginet C et al (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a v600e mutation. Haematologica 98:e20–e22

    Article  PubMed Central  PubMed  Google Scholar 

  4. Follows G, Sims H, Bloxham D et al (2013) Rapid response of biallelic braf v600e mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161:150–153

    Article  CAS  PubMed  Google Scholar 

  5. Munoz J, Schlette E, Kurzrock R (2013) Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a braf mutation. J Clin Oncol 31:e351–e352

    Article  PubMed  Google Scholar 

  6. Robert C, Arnault JP, Mateus C (2011) Raf inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177–182

    Article  CAS  PubMed  Google Scholar 

  7. Zimmer L, Hillen U, Livingstone E et al (2012) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective braf inhibition. J Clin Oncol 30:2375–2383

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Dietrich S, Hüllein S, Hundemer M et al (2013) Continued response off treatment after braf inhibition in refractory hairy cell leukemia. J Clin Oncol 31:e300–e303

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Straße 55, 79106, Freiburg, Germany

    Helga Maurer, Peter Haas, Michael Lübbert, Justus Duyster & Robert Zeiser

  2. Center for Cardiovascular Diseases, Freiburg University, Freiburg, Germany

    Tobias Wengenmayer

Authors
  1. Helga Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Wengenmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Lübbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Justus Duyster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Zeiser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Helga Maurer or Robert Zeiser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maurer, H., Haas, P., Wengenmayer, T. et al. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol 93, 1439–1440 (2014). https://doi.org/10.1007/s00277-013-1987-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1987-7

Keywords

Search

Navigation